CABOLIFE: A Prospective Non-Interventional Study on Effectiveness and Safety of Cabozantinib in Real-Life Setting for Previously Treated Patients with Neuroendocrine Tumours First published 30/10/2025 Last updated 28/01/2026 EU PAS number:EUPAS1000000752 Study Ongoing